BFM
STML

Boothbay Fund Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Boothbay Fund Management’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-92,152
Closed -$959K – 1090
2019
Q3 		$959K Buy
92,152
+4,525
+5% +$59.2K 0.09% 321
2019
Q2 		$1.34M Buy
+87,627
New +$1.27M 0.12% 207
2018
Q3 		– Sell
-12,400
Closed -$199K – 1003
2018
Q2 		$199K Buy
+12,400
New +$221K 0.02% 635

Other funds holding STML

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Boothbay Fund Management's STML Position: Q4 2019 in Review

Boothbay Fund Management sold out of Stemline Therapeutics, Inc. (STML) in Q4 2019, closing a stake of 92,152 shares — an estimated $959K sold.

Boothbay Fund Management first reported a position in STML in Q2 2018 and held it in 3 quarters. The position peaked at $1.34M in Q2 2019. 99 funds tracked by Wall St. Rank hold STML as of Q4 2019.

  • Boothbay Fund Management reported no remaining Stemline Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
  • Boothbay Fund Management sold 92,152 Stemline Therapeutics, Inc. shares in Q4 2019, an estimated $959K.
  • Boothbay Fund Management first reported a position in Stemline Therapeutics, Inc. in Q2 2018 and held it in 3 quarters.
  • Boothbay Fund Management's Stemline Therapeutics, Inc. position peaked at $1.34M in Q2 2019.
  • 99 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2019.

Based on Boothbay Fund Management's 13F filing for Q4 2019, filed 14 Feb 2020.